• PMH62 TRENDS IN ANTIDEPRESSANTS AND ANXIOLYTICS DRUG USAGE IN CROATIA AND SLOVENIA

    Nov 1, 2010, 00:00

  • PCV104 IMPACT OF POLICY-DRIVEN STATIN SWITCH PROGRAMS ON ADHERENCE AND PERSISTENCE

    Nov 1, 2010, 00:00

  • PHP115 THE INCORPORATION OF ECONOMIC EVIDENCE IN THE DUTCH CLINICAL PRACTICE GUIDELINES

    Nov 1, 2010, 00:00

  • PHP74 PRIMARY HEALTH CARE AND POTENTIALLY AVOIDABLE ADMISSIONS-A 10-YEAR ASSESSMENT FROM THE PERSPECTIVE OF A HEALTH CARE PLAN

    Nov 1, 2010, 00:00

  • PCN149 DECIDING UPON NEW AND EXPENSIVE TECHNOLOGIES IN HEALTH CARE- REAL OPTIONS ANALYSIS IN PROTON THERAPY

    Nov 1, 2010, 00:00

  • PCN3 RANDOMIZED, PLACEBO, CONTROLLED, DOUBLE-BLIND TRIAL OF MELATONIN IN CHOLANGIOCARCINOMA PATIENTS

    Nov 1, 2010, 00:00

  • PMS47 COMPARISON OF DOSING PATTERNS BETWEEN FIBROMYALGIA PATIENTS WITH HIGH VERSUS LOW DULOXETINE OR PREGABALIN COMPLIANCE

    Nov 1, 2010, 00:00

  • PCN35 CLINICAL AND ECONOMIC IMPLICATIONS OF SCREENING FOR KRAS MUTATIONS IN METASTATIC COLORECTAL CANCER PATIENTS IN SPAIN- A COST-EFFECTIVENESS AND BUDGET IMPACT MODEL

    Nov 1, 2010, 00:00

  • PCN16 MIXED TREATMENT COMPARISON OF BEVACIZUMAB-BASED THERAPIES RELATIVE TO DOUBLET-CHEMOTHERAPY COMBINATIONS TO ESTIMATE THE RELATIVE EFFICACY IN PROGRESSION-FREE SURVIVAL FOR TREATMENT OF FIRST-LINE ADVANCED OR METASTATIC NON-SMALL CELL L ...

    Nov 1, 2010, 00:00

  • PCN33 IMPACT BUDGETING IN CROATIA- FULVESTRANT EXAMPLE

    Nov 1, 2010, 00:00

  • PMC35 RECOMMENDATIONS ABOUT TRANSLATIONS IN THE FINAL FDA GUIDANCE ON PRO MEASURES-WHAT HAS CHANGED AND WHAT HAS REMAINED

    Nov 1, 2010, 00:00

  • PMC25 STATISTICAL DISTRIBUTIONS OF COST DATA IN PROBABILISTIC SENSITIVITY ANALYSIS

    Nov 1, 2010, 00:00

  • PMC21 USING GROWTH IN THE COST-EFFECTIVENESS THRESHOLD TO INFORM THE DIFFERENTIAL BETWEEN THE DISCOUNT RATES ON COSTS AND HEALTH EFFECTS- REASON TO BE CAUTIOUS?

    Nov 1, 2010, 00:00

  • PHP18 LIFETIME DISTRIBUTION OF MEDICAL COST IN KOREA

    Nov 1, 2010, 00:00

  • PHP60 HEALTH INSURANCE SUBSIDY OF SPA TREATMENT IN HUNGARY

    Nov 1, 2010, 00:00

  • PCN23 SIMULATION AND COMPARISON OF PROGRESSION-FREE-SURVIVAL OUTCOMES OF SEQUENTIAL TARGETED THERAPY IN METASTATIC RENAL-CELL CARCINOMA

    Nov 1, 2010, 00:00

  • PSY10 CHARACTERIZATION OF TREATMENT STRATEGIES FOR NEUROPATHIC PAIN- EVIDENCE FROM A PAIN SPECIALIST SETTING IN THAILAND

    Nov 1, 2010, 00:00

  • PCV93 THROMBOPROPHYLAXIS AFTER TOTAL KNEE REPLACEMENT- COST-UTILITY ANALYSIS OF RIVAROXABAN VERSUS ENOXAPARIN IN SLOVAKIA

    Nov 1, 2010, 00:00

  • PCV24 AN EPIDEMIOLOGICAL EVALUATION OF THE IMPACT OF PERCUTANEOUS CORONARY INTERVENTIONS ON THE LENGTH OF STAY AND MORTALITY OF PATIENTS HOSPITALIZED WITH ACUTE CORONARY SYNDROMES

    Nov 1, 2010, 00:00

  • PCV130 PRACTICE PATTERNS AND QUALITY OF LIFE IN ACUTE CORONARY SYNDROME PATIENTS IN 2008-2009- BASELINE RESULTS FOR AUSTRIA FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY II (APTOR II)

    Nov 1, 2010, 00:00

  • PCV41 ANTI-THROMBOLYTIC AGENT USE AND PATTERNS OF HEALTH-CARE UTILIZATION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION (AMI) USING KOREA NATIONAL HEALTH INSURANCE CLAIMS DATABASE

    Nov 1, 2010, 00:00

  • PMH24 HEALTH CARE UTILIZATION OF MAJOR DEPRESSIVE DISORDER PATIENTS

    Nov 1, 2010, 00:00

  • PMC29 USING DOZENS OF ATTRIBUTES WITHOUT INCREASING RESPONDENT BURDEN- HOW TO ADAPT LATENT VARIABLE MODELING FOR LINKING ATTRIBUTES ON SEPARATE CONJOINT SURVEYS

    Nov 1, 2010, 00:00

  • PIN67 MODELING G-DRG REVENUE WHEN HOSPITALIZATION DURATION FROM CLINICAL TRIALS IS AVAILABLE-THE CASE OF DORIPENEM VERSUS IMIPENEM IN TREATING VENTILATOR-ASSOCIATED PNEUMONIA (VAP) IN GERMANY

    Nov 1, 2010, 00:00

  • PCN102 COST-EFFECTIVENESS OF DIGITAL MAMMOGRAPHY IN A BREAST CANCER POPULATION-BASED SCREENING PROGRAM

    Nov 1, 2010, 00:00

  • PMS5 PRIMARY ANTI-TNF FAILURES EXPERIENCE SUPERIOR CLINICAL RESPONSES TO A SECOND ANTI-TNF AGENT THAN SECONDARY FAILURES- ANALYSIS OF THE ALBERTA RHEUMATOID ARTHRITIS BIOLOGICS REGISTRY

    Nov 1, 2010, 00:00

  • PHP8 INTERVENTIONS TO REDUCE HOSPITAL READMISSIONS IN THE ELDERLY

    Nov 1, 2010, 00:00

  • PIN16 HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH HEPATITIS A IN A US COMMERCIALLY INSURED POPULATION

    Nov 1, 2010, 00:00

  • PIH10 COST-EFECTIVENESS OF QUADRIVALENT AND BIVALENT HPV VACCINATIONS AGAINST CERVICAL CANCER

    Nov 1, 2010, 00:00

  • PIH36 PATIENT SATISFACTION WITH FOLLITROPIN ALFA PREFILLED PEN IN WOMEN UNDERGOING OVARIAN STIMULATION- ELABORATION AND VALIDATION OF VENUSF QUESTIONNAIRE

    Nov 1, 2010, 00:00

  • PCN17 NO CONCLUSIVE EVIDENCE FROM RANDOMIZED CONTROLLED TRIALS (RCTS) FOR IMPROVED SURVIVAL WITH SECOND-LINE TREATMENT OPTIONS, IN PATIENTS WITH METASTATIC HORMONEREFRACTORY PROSTATE CANCER (MHRPC) PREVIOUSLY TREATED WITH DOCETAXEL

    Nov 1, 2010, 00:00

  • PDB20 OLDER WOMEN WITH DIABETES- CARDIOVASCULAR MEDICATION USE AND QUALITY OF LIFE

    Nov 1, 2010, 00:00

  • PHP5 THE ESSENTIAL MEDICINE SYSTEM IN CHINA- STRATEGIES AND CHALLENGES

    Nov 1, 2010, 00:00

  • PIH1 EMERGENCY CONTRACEPTION FOR UNINTENDED PREGNANCY- ROLE OF ULIPRISTAL, A NOVEL PROGESTERONE RECEPTOR MODULATOR

    Nov 1, 2010, 00:00

  • PMC11 ARE THRESHOLD RANGES FOR COST PER QALY A BARRIER TO RESEARCH FOR LIFE EXTENDING TREATMENTS

    Nov 1, 2010, 00:00

  • PDB2 LONG-TERM HEALTH OUTCOMES OF TREATMENT WITH LIRAGLUTIDE VERSUS GLIMEPRIRIDE IN TYPE 2 DIABETES PATIENTS IN ASIAN SETTING

    Nov 1, 2010, 00:00

  • PRS38 SYMPTOMATIC COMORBIDITIES AND HEALTH-RELATED QUALITY OF LIFE IN COPD IN THE EUROPEAN UNION

    Nov 1, 2010, 00:00

  • PMH23 COSTS OF A COMMUNITY SUPPORT PROGRAM FOR DEPRESSION- RESULTS FROM THE BEAT THE BLUES (BTB) TRIAL

    Nov 1, 2010, 00:00

  • PIN24 PATTERNS OF ANTIMICROBIAL DRUG USE IN INDIAN INTENSIVE CARE UNIT SETTINGS

    Nov 1, 2010, 00:00

  • PIN20 PSEUDOMONAS AERUGINOSA RELATED ECONOMIC BURDEN STRATIFIED BY COMORBIDITY IN CYSTIC FIBROSIS PATIENTS

    Nov 1, 2010, 00:00

  • PCN126 REVIEW OF PATIENT-REPORTED OUTCOMES IN PHASE II ONCOLOGY CLINICAL TRIALS

    Nov 1, 2010, 00:00

  • PCV96 PRIORITIZING FURTHER RESEARCH USING THE EXPECTED VALUE OF PERFECT INFORMATION-APPLICATION TO VENOUS THROMBOEMBOLISM PROPHYLAXIS POST TOTAL HIP REPLACEMENT

    Nov 1, 2010, 00:00

  • PCN34 BUDGET IMPACT ANALYSIS OF CAPECITABINE IN ADJUVANT TREATMENT OF PATIENTS WITH RESECTED DUKESS PERSPECTIVES

    Nov 1, 2010, 00:00

  • PMC61 MONITORING OF HEALTH ECONOMIC DATA IN CLINICAL TRIALS

    Nov 1, 2010, 00:00

  • PHP34 PATIENT ACCESS TO INNOVATIVE MEDICINES IN HUNGARY

    Nov 1, 2010, 00:00

  • PMC45 GLOBAL INDUSTRY USE OF ELECTRONIC PATIENT-REPORTED OUTCOME INSTRUMENTS- PRELIMINARY RESULTS FROM A 2010 EPRO SURVEY

    Nov 1, 2010, 00:00

  • PSY20 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IS COSTLY FOR THE HEALTH CARE SYSTEM AND WORKPLACE- A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2010, 00:00

  • PMS57 HEALTH-RELATED QUALITY OF LIFE AFTER TOTAL KNEE REPLACEMENT OR UNICOMPARTMENTAL KNEE ARTHROPLASTY IN AN URBAN ASIAN POPULATION

    Nov 1, 2010, 00:00

  • PHP123 PHARMACY NETWORK DEVELOPMENT DURING ECONOMIC TRANSITION IN POLAND

    Nov 1, 2010, 00:00

  • PCN131 HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN CERVICAL CANCER- CLINICAL SIGNIFICANCE AND METHODOLOGICAL ISSUES

    Nov 1, 2010, 00:00

  • PMC52 TREATMENT SATISFACTION WITH MEDICATION- A REVIEW OF CONCEPTUAL FRAMEWORKS AND APPLICATIONS

    Nov 1, 2010, 00:00

  • PCV47 A NATIONAL SURVEY OF SOCIETAL COST OF ACUTE CORONARY SYNDROME IN SOUTH KOREA

    Nov 1, 2010, 00:00

  • PHP24 CRITICAL ASSESSMENT OF BELGIAN REIMBURSEMENT DOSSIERS OF ORPHAN DRUGS

    Nov 1, 2010, 00:00

  • PCN25 DID THE UPTAKE OF NEW TREATMENT OPTIONS CHANGE THE TREATMENT STRATEGY IN PATIENTS WITH COLORECTAL CANCER AND PRIMARY NONRESECTABLE METASTASES? THE RESULTS OF LARGE POPULATION-BASED SURVEY IN GERMANY 2006-2007

    Nov 1, 2010, 00:00

  • PCN26 ESTIMATION OF THE EPIDEMIOLOGICAL EFFECT OF RITUXIMAB FOR THE TREATMENT OF AGGRESSIVE NON-HODGKIN LYMPHOMA

    Nov 1, 2010, 00:00

  • PSY64 SEQUENCE OF TREATMENT IN IMMUNE THROMBOCYTOPENIA (ITP) PATIENTS- RESULTS OF A MEDICAL RECORD REVIEW FROM EIGHT HOSPITALS IN SPAIN

    Nov 1, 2010, 00:00

  • PSY4 COMPARATIVE COST-EFFECTIVENESS ANALYSES OF IRON CHELATING THERAPIES IN TRANSFUSION-DEPENDENT THALASSAEMIA POPULATION IN THAILAND

    Nov 1, 2010, 00:00

  • PMS58 CLINICAL OUTCOMES AND CHANGES IN QUALITY OF LIFE IN WOMEN WITH OSTEOPOROSIS TREATED WITH TERIPARATIDE- 36 MONTH RESULTS OF THE FRENCH PATIENTS PARTICIPATING IN THE EUROPEAN FORSTEO OBSERVATIONAL STUDY (EFOS)

    Nov 1, 2010, 00:00

  • PIH9 COST COMPARISON OF MIDWIFE-LED VERSUS OTHER MODELS OF CARE FOR CHILDBEARING WOMEN FROM THE PRIVATE PAYER PERSPECTIVE IN BRAZIL

    Nov 1, 2010, 00:00

  • PHP87 THE ROLE OF VALUE OF INFORMATION ANALYSIS IN HEALTH CARE RESEARCH PRIORITY SETTING-A THEORETICAL CASE STUDY

    Nov 1, 2010, 00:00

  • PIN55 RISK SCORES PREDICTING RESOURCE USE OF HEPATITIS C PATIENTS IN GERMANY-AN ANALYSIS OF SICK FUND CLAIMS DATA

    Nov 1, 2010, 00:00

  • PHP69 MOBILE MEDICAL RECORD-A LIFE SAVING TOOL

    Nov 1, 2010, 00:00

  • PCV48 ST. VINCENTS PRIVATE HOSPITAL VENOUS THROMBOEMBOLISM PREVENTION PROJECT- ANALYSIS OF REDUCED COST AND IMPROVED CLINICAL OUTCOMES

    Nov 1, 2010, 00:00

  • PMS12 PROJECTION OF SURGICAL LOADS OF HIP AND KNEE

    Nov 1, 2010, 00:00

  • PMC57 BIAS IS WORSE THAN NOISE- HANDLING MISSING DATA FOR CONFOUNDERS IN OBSERVATIONAL STUDIES

    Nov 1, 2010, 00:00

  • PUK35 PATIENTS WITH BPH- RESULTS AT 6 MONTHS FOLLOWING TREATMENT WITH PHYTOTHERAPY VERSUS OTHER TREATMENTS

    Nov 1, 2010, 00:00

  • PIH28 DETERMINANTS OF HEALTH SERVICE UTILIZATION FOLLOWING THE 2004 TSUNAMI IN THAILAND

    Nov 1, 2010, 00:00

  • PHP86 SUCCESSFUL IMPLEMENTATION OF COVERAGE WITH EVIDENCE DEVELOPMENT SCHEMES- PRACTICAL EXPERIENCES IN SEVERAL WESTERN JURISDICTIONS

    Nov 1, 2010, 00:00

  • PIH64 A CONCEPTUAL FRAMEWORK FOR A PATIENT REPORTED OUTCOMES MEASURE OF ATTITUDES TOWARD COMPLEMENTARY AND ALTERNATIVE MEDICINE IN MENOPAUSE

    Nov 1, 2010, 00:00

  • PCN57 EXAMINING PATIENT-BASED COSTS FOR IRINOTECAN CHEMOTHERAPY- UK PRACTICE-BASED MICROCOSTING STUDY

    Nov 1, 2010, 00:00

  • PCN120 UTILITY AND WORK PRODUCTIVITY DATA FOR ECONOMIC EVALUATION OF BREAST CANCER THERAPIES IN THE NETHERLANDS AND SWEDEN

    Nov 1, 2010, 00:00

  • PCV76 COST-EFFECTIVENESS ANALYSIS OF DRONEDARONE IN PATIENTS WITH ATRIAL FIBRILLATION IN MEXICO- A WITHIN TRIAL ANALYSIS BASED ON ATHENA TRIAL

    Nov 1, 2010, 00:00

  • PCN117 UTILITY ELICITATION STUDY IN THE UK GENERAL PUBLIC FOR LATE STAGE CHRONIC LYMPHOCYTIC LEUKEMIA

    Nov 1, 2010, 00:00

  • PCN69 COST-EFFECTIVENESS ANALYSIS OF DASATINIB 100 MG VS. IMATINIB 800 MG IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA IN SPAIN

    Nov 1, 2010, 00:00

  • PSY27 A HEALTH ECONOMIC EVALUATION OF THE SWITCH OF ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN PATIENTS WITH RENAL FAILURE UNDERGOING HEMODIALYSIS

    Nov 1, 2010, 00:00

  • PHP130 TRENDS IN COST CONTAINMENT MEASURES

    Nov 1, 2010, 00:00

  • PMC20 THE OPTIMAL NUMBER OF MONTE CARLO SIMULATIONS TO BE PERFORMED IN PROBABILISTIC SENSITIVITY ANALYSIS- EMPIRICAL EVIDENCE FROM ECONOMIC MODELS CONSTRUCTED FOR SUBMISSION TO THE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

    Nov 1, 2010, 00:00

  • PMC53 COMPARISON OF METHODS FOR ITEM GENERATION AND PRETESTING OF FIVE LYMPHOEDEMA-SPECIFIC HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRES

    Nov 1, 2010, 00:00

  • PIN2 SURGICAL SITE INFECTION IN INDIA- A SYSTEMATIC REVIEW OF THE INCIDENCE AND ECONOMIC BURDEN

    Nov 1, 2010, 00:00

  • PCN25 COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL AS A SECOND- OR THIRD-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN KOREA

    Nov 1, 2010, 00:00

  • PMS68 PHYSICIANS STATED PREFERENCES OVER BENEFITS AND RISKS ASSOCIATED WITH NSAID USE IN PATIENTS WITH OSTEOARTHRITIS IN UNITED KINGDOM

    Nov 1, 2010, 00:00

  • PCN96 A UK COST-UTILITY ANALYSIS OF PACLITAXEL ALBUMIN COMPARED TO SOLVENT-BASED PACLITAXEL MONOTHERAPY AND DOCETAXEL MONOTHERAPY FOR PRETREATED METASTATIC BREAST CANCER (MBC)

    Nov 1, 2010, 00:00

  • PCV106 THE MISSING PIECE BETWEEN TREATMENT EXPERIENCE AND INTENTION TO PERSIST-TESTING THE INTERNAL CONSISTENCY RELIABILITY AND PREDICTIVE VALIDITY OF ACCEPTABILITY

    Nov 1, 2010, 00:00

  • PIN53 COST-UTILITY ANALYSIS OF NEW PNEUMOCOCCAL CONJUGATE VACCINES IN THE REGIONAL IMMUNIZATION PROGRAM OF THE AUTONOMOUS REGION OF MADRID-IMPACT ON INVASIVE PNEUMOCOCCAL DISEASE

    Nov 1, 2010, 00:00

  • PSY18 DIRECT MEDICAL COSTS OF LIQUID INTRAVENOUS IMMUNOGLOBULINS IN CHILDREN, ADOLESCENTS AND ADULTS IN SPAIN

    Nov 1, 2010, 00:00

  • PND3 A RAPID REVIEW OF ECONOMIC EVALAUTIONS OF DONEPEZIL, RIVASTIGMINE, GALANTAMINE AND MEMANTINE FOR ALZHEIMERS DISEASE (AD)

    Nov 1, 2010, 00:00

  • CN1 EFFICACY OF THE COMBINATION BEVACIZUMAB PLUS CHEMOTHERAPY (BEV-CT) COMPARED TO CT ALONE IN PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)- SYSTEMATIC REVIEW (SR) AND META-ANALYSIS (MA)

    Nov 1, 2010, 00:00

  • PHP96 SENSE OF COHERENCE-AS MEDIATING FACTOR IN REMAINING EMPLOYED IN HEALTH CARE PROFESSION

    Nov 1, 2010, 00:00

  • PMH67 FACTORS ASSOCIATED WITH ANTIPSYCHOTICS USE AMONG COMMUNITY-DWELLING OLDER PERSONS WITH DEMENTIA

    Nov 1, 2010, 00:00

  • CE4 ECONOMIC EVALUATION OF REHABILITATION SERVICES FOR INPATIENT WITH STROKE IN TWO REGIONAL HOSPITALS IN THAI CONTEXT

    Nov 1, 2010, 00:00

  • PMS26 HIP FRACTURES IN THE ELDERLY- COST OF ILLNESS STUDY UNDER A PUBLIC HOSPITAL PERSPECTIVE IN RIO DE JANEIRO, BRAZIL

    Nov 1, 2010, 00:00

  • PRS47 USE OF PROPENSITY SCORE MATCHING, STANDARD REGRESSION ANALYSIS AND INSTRUMENTAL VARIABLE METHOD IN OUTCOMES RESEARCH STUDIES- A COMPARATIVE ANALYSIS

    Nov 1, 2010, 00:00

  • PUK25 USING GENETIC POLYMORPHISM AS A STRATEGY TO ESTIMATE THE POTENTIAL COST-EFFECTIVENESS OF PHARMACOLOGICAL CCR5 BLOCKADE IN DIALYSIS PATIENTS

    Nov 1, 2010, 00:00

  • PCV136 ATRIAL FIBRILLATION MANAGEMENT PATTERNS IN GREECE

    Nov 1, 2010, 00:00

  • PMS37 THE COST-EFFECTIVENESS OF ABATACEPT IN COMBINATION WITH METHOTREXATE FOR THE TREATMENT OF PATIENT WITH ACTIVE RHEUMATOID ARTHRITIS AFTER AN INADEQUATE RESPONSE TO METHOTREXATE IN THE UNITED KINGDOM

    Nov 1, 2010, 00:00

  • PCV83 PILOTING THE DEVELOPMENT OF A COST-EFFECTIVE EVIDENCEINFORMED CLINICAL PATHWAY- MANAGING HYPERTENSION IN JORDANIAN PRIMARY CARE

    Nov 1, 2010, 00:00

  • PCV58 SUBSTITUTION INFLUENCE FROM MARK DRUGS TO GENERICS IN THE ARTERIAL HYPERTENSION THERAPEUTIC COMPLIANCE AND THE DYSLIPEMIA IN A POPULATION SETTING

    Nov 1, 2010, 00:00

  • PMH45 DISCONTINUATION OF DIFFERENT ANTIPSYCHOTIC MEDICATIONS AFTER DISCHARGE FROM ACUTE CARE FOR PERSONS WITH SCHIZOPHRENIA

    Nov 1, 2010, 00:00

  • PCV17 RESPONSE PROFILES OF SILDENAFIL CITRATE ON EXERCISE CAPACITY, HEMODYNAMIC FUNCTION, AND HEALTH-RELATED QUALITY OF LIFE IN CHILDREN WITH PULMONARY ARTERIAL HYPERTENSION

    Nov 1, 2010, 00:00

  • PMS22 ECONOMIC BURDEN OF OSTEOPOROSIS-RELATED FRACTURE HOSPITALIZATIONS IN FRANCE

    Nov 1, 2010, 00:00

  • PND37 PATIENT AND PHYSICIAN GLOBAL PERCEPTION OF LEVODOPA/ CARBIDOPA/ENTACAPONE VS. LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSONS DISEASE EXPERIENCING EARLY WEARING-OFF

    Nov 1, 2010, 00:00

  • PSY5 A MARKOV MODEL TO ESTIMATE THE EFFECT OF CANAKINUMAB ON THE PROGRESSION OF AA AMYLOIDOSIS IN PATIENTS WITH CRYOPYRIN-ASSOCIATED PERIODIC-FEVER SYNDROMES (CAPS)

    Nov 1, 2010, 00:00

  • HT2 INFLUENCE OF HTA AND HOSPITAL FUNDING SYSTEMS ON PATIENT ACCESS TO INNOVATIVE MEDICINES- EXAMPLE OF ADVANCED RENAL CELL CANCER IN WESTERN EUROPE

    Nov 1, 2010, 00:00

  • PCV25 RISK OF STROKE AND PREVENTATIVE STEPS AMONG PATIENTS DIAGNOSED WITH ATRIAL FIBRILLATION IN EUROPE

    Nov 1, 2010, 00:00

  • PIH26 DEVELOPMENT OF A SEGMENTATION MODEL TO IDENTIFY HEALTH CARE DEMAND AND RELATED COSTS ATTRIBUTABLE TO POPULATIONS CHARACTERISTICS

    Nov 1, 2010, 00:00

  • PGI29 PPI GENERAL PRACTITIONERS PRESCRIBING IN THE TREATMENT OF ACID-RELATED DISORDERS-THE IMPACT OF GENERIC PPI LAUNCH INTO THE PHARMACEUTICAL MARKET IN ITALY

    Nov 1, 2010, 00:00

  • PUK12 THE ECONOMIC IMPACT OF RENAL GRAFT FAILURE-A COST ANALYSIS IN A UK SETTING

    Nov 1, 2010, 00:00

  • PCN20 MAINTENANCE ERLOTINIB VERSUS PEMETREXED FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER- INDIRECT COMPARISON APPLYING REAL-LIFE OUTCOMES

    Nov 1, 2010, 00:00

  • PIH35 DETERMINATION OF COMMUNITY PHARMACYS DISPENSING COST IN MALAYSIA

    Nov 1, 2010, 00:00

  • CN4 HPV-BASED PRIMARY CERVICAL CANCER SCREENING IN GERMANY. COST-EFFECTIVENESS RESULTS FROM A DECISION-ANALYTIC MODELING STUDY

    Nov 1, 2010, 00:00

  • PMH52 A SHORT 12-ITEM ZARIT BURDEN INVENTORY FOR THE ASSESSMENT OF DEMENTIA CAREGIVERS AS OBTAINED BY ITEM RESPONSE THEORY

    Nov 1, 2010, 00:00

  • PHP126 PATIENT ACCESS SCHEMES (PAS) IN THE UK COMING OF AGE-WHAT IMPACT WILL THEY HAVE ON OTHER EU COUNTRIES LIKE ITALY?

    Nov 1, 2010, 00:00

  • DU2 THE UTILIZATION OF PROPHYLACTIC ANTITHROMBOTIC AGENTS AFTER MAJOR ORTHOPEDIC SURGERIES-A POPULATION-BASED STUDY IN TAIWAN

    Nov 1, 2010, 00:00

  • PND42 THE RELATIONSHIP BETWEEN SOME INDICATORS INFLUENCING THE QUALITY OF LIFE OF PEOPLE WITH DOWNS SYNDROME LOOKED AFTER IN THE FAMILY AND PARENTAL QUALIFICATION IN CONNECTION WITH A STUDY CARRIED OUT IN HUNGARY

    Nov 1, 2010, 00:00

  • PMC43 DATA POOLING OF PATIENT-REPORTED OUTCOMES IN CLINICAL TRIALS- EVALUATION OF STATISTICAL TECHNIQUES FOR ASSESSING MEASUREMENT EQUIVALENCE

    Nov 1, 2010, 00:00

  • PUK7 THE PHARMACY BUDGET IMPACT OF EXTENDING REIMBURSEMENT OF LANTHANUM CARBONATE TO TREATMENT OF HYPERPHOSPHATEMIA (1.78 MMOL/L) IN PATIENTS WITH CHRONIC KIDNEY DISEASE PRE-DIALYSIS IN FRANCE AND THE UNITED KINGDOM

    Nov 1, 2010, 00:00

  • PMS6 COMPARISON OF RECENTLY REGISTERED BIOLOGICAL DRUGS WITH AVAILABLE THERAPIES IN RHEUMATOID ARTHRITIS- METHODOLOGICAL ISSUES TO CONSIDER FOR META-ANALYSIS

    Nov 1, 2010, 00:00

  • DB4 ECONOMIC EVALUATION OF THIAZOLIDINEDIONES AS ADD-ON THERAPY FOR TREATMENT OF TYPE 2 DIABETIC PATIENTS IN THE TAIWANESE NATIONAL HEALTH INSURANCE SYSTEM

    Nov 1, 2010, 00:00

  • PMS31 THE IMPACT OF CHANGES IN ADALIMUMAB, ETANERCEPT, AND INFLIXIMAB DOSES ON THE COSTS OF TREATING RHEUMATOID ARTHRITIS

    Nov 1, 2010, 00:00

  • PND18 48-HOUR INFUSION OF METHYLPREDNISOLONE IS A COST-EFFECTIVE INTERVENTION FOR TRAUMATIC SPINAL CORD INJURY

    Nov 1, 2010, 00:00

  • PSS27 COSMETI QOL-A TOOL FOR ASSESSING QUALITY OF LIFE IN COSMETIC DERMATOLOGY

    Nov 1, 2010, 00:00

  • PDB7 ESTIMATED COSTS OF INCLUDING GROWTH HORMONE REPLACEMENT THERAPY INTO THE UNIVERSAL COVERAGE BENEFIT PACKAGE IN THAILAND

    Nov 1, 2010, 00:00

  • CN1 CERVICAL CANCER SCREENING PROGRAM IN THAILAND- ASSESSMENT OF SERVICE COVERAGE AND DETERMINANTS OF PROGRAM UPTAKE

    Nov 1, 2010, 00:00

  • PIH6 IMPACT OF ROTAVIRUS VACCINATION ON ACUTE GASTROENTERITIS RELATED EMERGENCY ROOM VISITS IN CHILDREN FIVE YEARS OLD IN BELGIUM

    Nov 1, 2010, 00:00

  • PMH58 MODELING PROGRESSION IN DEMENTIA- ASSESSING THE PERFORMANCE OF FIVE CLINICAL MEASURES IN SPANISH SUBJECTS AND CAREGIVERS

    Nov 1, 2010, 00:00

  • PHP36 ANALYSIS OF THE TECHNICAL EFFICIENCY IN THREE TEACHING HOSPITALS IN MALAYSIA

    Nov 1, 2010, 00:00

  • PCV79 COST-EFFECTIVENESS OF DRONEDARONE IN SOUTH KOREA

    Nov 1, 2010, 00:00

  • PMC18 MULTI-NATIONAL CHART REVIEW STUDIES IN EUROPE- OPPORTUNITIES AND CHALLENGES

    Nov 1, 2010, 00:00

  • PCV33 ESTIMATING THE FINANCIAL IMPLICATIONS TO THE UK NHS OF INTRODUCING COREVALVE ALONGSIDE MEDICAL MANAGEMENT FOR THE TREATMENT OF SEVERE AORTIC STENOSIS

    Nov 1, 2010, 00:00

  • PDB49 PHARMACOECONOMICS MODELING OF LONG TERM RESULTS OF TYPE 2 DIABETES MELLITUS TREATMENT IN PATIENTS USING MODERN INSULIN ANALOGUES IN CONTRAST TO ORAL ANTIDIABETIC DRUGS OR DIET

    Nov 1, 2010, 00:00

  • PCV3 MIXED TREATMENT COMPARISON OF PROPHYLAXIS REGIMENS FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN TOTAL HIP REPLACEMENT, HIP FRACTURE, TOTAL KNEE REPLACEMENT AND GENERAL SURGERY

    Nov 1, 2010, 00:00

  • PUK6 POST RENAL TRANSPLANT PATIENT SURVIVAL AND THE COMBINED ADVERSE EFFECT OF POOR RENAL FUNCTION AND NEW ONSET DIABETES MELLITUS

    Nov 1, 2010, 00:00

  • PHP16 A COMPREHENSIVE STUDY OF GENERIC DRUG ENTRY IN THE UNITED STATES- 1991-2008

    Nov 1, 2010, 00:00

  • PDB87 STANDARDS FOR THE ASSESSMENT OF ANTIDIABETIC DRUGS-THE IQWIG PERSPECTIVE

    Nov 1, 2010, 00:00

  • PHP30 MARKET ACCESS, AFFORDABILITY AND PRICE COMPONENTS OF MEDICINES IN THE UNITED ARAB EMIRATES (UAE)

    Nov 1, 2010, 00:00

  • PMS50 PATIENTS STATED HEALTH-OUTCOME PREFERENCES FOR CONFOUNDED PATIENT-REPORTED OUTCOME DOMAINS FOR OSTEOARTHRITIS

    Nov 1, 2010, 00:00

  • PCV20 COMPLIANCE WITH ANTIHYPERTENSIVE AGENTS AND THE ONSET OF END-STAGE RENAL DISEASE

    Nov 1, 2010, 00:00

  • PDB65 THE METHODOLOGICAL QUALITY AND EFFECTIVENESS OF ADHERENCE INTERVENTIONS- A REVIEW OF DIABETES TYPE II INTERVENTIONS

    Nov 1, 2010, 00:00

  • PDB72 FURTHER DEVELOPMENTS OF THE QUALITY OF LIFE ASSESSMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS (QOL-AGHDA)

    Nov 1, 2010, 00:00

  • PIH33 PSYCHOMETRIC VALIDATION OF AN ABBREVIATED VERSION OF THE SEXUAL FUNCTION QUESTIONNAIRE (ASFQ)

    Nov 1, 2010, 00:00

  • PND11 NURSE COSTING SURVEY FOR THE MANAGEMENT OF ADVERSE EVENTS IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH DISEASE-MODIFYING DRUGS IN THE UK

    Nov 1, 2010, 00:00

  • PDB57 LOWER TREATMENT COSTS WITH INSULIN GLARGINE COMPARED TO INSULIN DETEMIR IN TYPE 1 DIABETES PATIENTS TREATED WITH A BASAL-BOLUS REGIMEN IN GERMANY

    Nov 1, 2010, 00:00

  • PSS21 AN ECONOMIC ANALYSIS OF TACROLIMUS OINTMENT MAINTENANCE USE (TWICE WEEKLY) VERSUS STANDARD USE IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS IN NORWAY AND FINLAND

    Nov 1, 2010, 00:00

  • PCN7 ESTIMATION ON THE INCIDENCE OF SELECTED CANCERS IN CHINA, 2004

    Nov 1, 2010, 00:00

  • PIH30 THE DRINKING BEHAVIOR OF RESIDENTS OF A VILLAGE IN AN INDUSTRIAL PARK AREA-THE CURRENT SITUATION AND REASONS BEHIND THIS BEHAVIOR

    Nov 1, 2010, 00:00

  • PSY50 HEALTH-RELATED QUALITY OF LIFE, HEALTH UTILITIES, AND WORK PRODUCTIVITY ASSOCIATED WITH SPECIFIC OBESITY-RELATED COMORBIDITIES

    Nov 1, 2010, 00:00

  • PCV87 USING VALUE OF INFORMATION ANALYSIS IN COMBINATION WITH AN EARLY STAGE MODEL OF COREVALVE FOR SEVERE AORTIC STENOSIS TO INFORM FUTURE RESEARCH NEEDS

    Nov 1, 2010, 00:00

  • PDB17 GLYCATED HEMOGLOBIN AS A SURROGATE MARKER FOR THE APPEARANCE AND PROGRESSION OF MACRO VASCULAR COMPLICATIONS IN TYPE 2 DIABETES MELLITUS- SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2010, 00:00

  • PCN95 A MARKOV MODEL TO ESTIMATE THE COST-EFFECTIVENESS OF OMACETAXINE IN CHRONIC MYELOID LEUKEMIA

    Nov 1, 2010, 00:00

  • PND30 COST-UTILITY ANALYSIS OF LACOSAMIDE ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL-ONSET SEIZURES IN EPILEPTIC PATIENTS IN BELGIUM

    Nov 1, 2010, 00:00

  • PUK5 COMPARISON OF SF-6D, EQ-5D AND VAS IN HEMODIALYSIS THAI PATIENT

    Nov 1, 2010, 00:00

  • PIN14 PUBLIC HEATH AND ECONOMIC IMPACT OF ROTAVIRUS VACCINATION IN KOREA

    Nov 1, 2010, 00:00

  • PMS7 A COST-EFFECTIVENESS ANALYSIS OF OSTEOPOROSIS TREATMENT FOR FRACTURE PREVENTION IN POSTMENOPAUSAL THAI WOMEN- A COMPARISON OF SEVEN TREATMENT OPTIONS

    Nov 1, 2010, 00:00

  • PDB33 EVALUATION OF COST AND CLINICAL OUTCOMES BY HBA1C AT DIAGNOSIS USING VARIOUS DIABETES TREATMENT STRATEGIES

    Nov 1, 2010, 00:00

  • PSS31 VISION-RELATED QUALITY OF LIFE INSTRUMENTS (QOL) AFTER REFRACTIVE CATARACT SURGERY

    Nov 1, 2010, 00:00

  • PIH12 GOLD STAGE AND DURATION OF HOSPITAL ADMISSION DETERMINES SIZE AND STRUCTURE OF COPD RELATED DIRECT MEDICAL COSTS IN ELDERLY

    Nov 1, 2010, 00:00

  • PHP50 FRAGMENTED HEALTH CARE SYSTEM-SOLVING THE JIGSAW PUZZLE

    Nov 1, 2010, 00:00

  • PIN34 A CONTINUOUS-TIME ECONOMIC MODEL TO EVALUATE RALTEGRAVIR USE STRATEGIES IN TREATMENT-NAIVE HIV-1 PATIENTS IN PORTUGAL

    Nov 1, 2010, 00:00

  • PIH34 DRUG COST REDUCTION IN LONG-TERM CARE PATIENTS WITH CHRONIC DISEASE

    Nov 1, 2010, 00:00

  • PCV5 ASSESSMENT OF LIPID ABNORMALITIES- PREVALENCE AND ATTAINMENT OF LIPID GOALS/NORMAL LEVELS AMONG ADULTS IN THAILAND

    Nov 1, 2010, 00:00

  • PMS1 HIGHER COMORBIDITIES IN PATIENTS WITH GOUT VS. WITHOUT GOUT IN THE US GENERAL POPULATION-THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES) 2007-2008

    Nov 1, 2010, 00:00

  • PMH44 AN OBSERVATIONAL STUDY OF THE BURDEN OF INFORMAL CAREGIVERS TO OUT-PATIENTS WITH SCHIZOPHRENIA SPECTRUM DISORDERS

    Nov 1, 2010, 00:00

  • RS2 PAYER ROADBLOCKS TO RISK-SHARING AGREEMENTS AROUND THE WORLD- WHERE, WHEN AND HOW?

    Nov 1, 2010, 00:00

  • PDB27 A REVIEW OF HEALTH TECHNOLOGY ASSESSMENTS OF DIABETES IN ASIA AND OCEANIA

    Nov 1, 2010, 00:00

  • PCN78 OST-EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH IMATINIB MESYLATE IN PATIENTS AFTER RESECTION OF LOCALIZED PRIMARY GASTROINTESTINAL STROMAL TUMOR

    Nov 1, 2010, 00:00

  • PDB14 HOSPITALIZATION ATTRIBUTED TO DIABETES MELLITUS AND ITS COMPLICATIONS IN THE PRIVATE HEALTH-CARE SYSTEM IN RIBEIRO PRETO REGION, BRAZIL

    Nov 1, 2010, 00:00

  • PCN21 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT HORMONAL TREATMENTS FOR POSTMENOPAUSAL HORMONE-RECEPTOR POSITIVE EARLY BREAST CANCER IN KOREAN CONTEXT

    Nov 1, 2010, 00:00

  • PMH8 EXCESS MORTALITY RISK IN PATIENTS WITH PSYCHOSIS HOSPITALIZED IN JAPANESE NATIONAL MENTAL HOSPITALS

    Nov 1, 2010, 00:00

  • PHP119 ROLE OF QUALITY IMPROVEMENT FOR MANAGEMENT OF SURGICAL BLEED COMPLICATIONS (SBCS)

    Nov 1, 2010, 00:00

  • PDB50 ASSESSING THE INFLUENCE OF INCORPORATING SECONDARY CARDIOVASCULAR EVENTS INTO A TYPE 2 DIABETES MELLITUS (T2DM) COST-EFFECTIVENESS MODEL

    Nov 1, 2010, 00:00

  • PCV44 EVALUATION OF CLINICAL AND DIRECT ECONOMIC OUTCOMES BETWEEN STATIN AND FENOFIBRATE AND STATIN MONOTHERAPY FOLLOWING AN INITIAL ACUTE CORONARY EVENT

    Nov 1, 2010, 00:00

  • PCN21 FIRST-LINE BEVACIZUMAB-BASED THERAPY VERSUS PEMETREXED CISPLATIN FOR THE TREATMENT OF ADVANCED ADENOCARCINOMA NONSQUAMOUS NON-SMALL CELL LUNG CANCER- INDIRECT COMPARISON APPLYING REAL-LIFE OUTCOMES

    Nov 1, 2010, 00:00

  • PIN72 BRAZILIAN STD/AIDS PROGRAMME- EXPENDITURE ON ANTIRETROVIRAL DRUGS AND EPIDEMIC INDICATORS DURING THE PERIOD 2004-2008

    Nov 1, 2010, 00:00

  • PIN40 COST-EFFECTIVENESS OF PNEUMOCOCCAL VACCINATION AMONG INFANTS IN RUSSIA- ECONOMIC EVALUATION OF THE PNEUMOCOCCAL 7-VALENT CONJUGATE VACCINE

    Nov 1, 2010, 00:00

  • PIH30 PERSISTENCE TO POSTMENOPAUSAL OSTEOPOROSIS (PMO) TREATMENTS IN A REGION OF SPAIN

    Nov 1, 2010, 00:00

  • PIH45 HEALTH-RELATED QUALITY OF LIFE (HRQOL) OF FERTILE WOMEN USERS OF CONTRACEPTIVE METHODS

    Nov 1, 2010, 00:00

  • PIH50 MATERNAL MORTALITY RATE IN INDIA-A COMPREHENSIVE LITERATURE REVIEW

    Nov 1, 2010, 00:00

  • PHP23 ECONOMIC EVALUATION OF TELEHEALTH/TELEMEDICINE AND COST-EFFECTIVENESS ARGUMENT AMONG KEY DECISION-MAKERS

    Nov 1, 2010, 00:00

  • PCV38 CLINICAL AND ECONOMICAL BENEFITS OF THE USE OF REMOTE MONITORING WITH CARELINK IN CENTRO MDICO NACIONAL 'LA RAZA', IMSS MEXICO

    Nov 1, 2010, 00:00

  • PHP13 IMPLEMENTATION OF THE TRANSPARENCY DIRECTIVE IN HUNGARY

    Nov 1, 2010, 00:00

  • PGI21 RELATIONSHIP BETWEEN PATIENT PREFERENCES FOR 5-ASA THERAPIES AND SELF-REPORTED ADHERENCE

    Nov 1, 2010, 00:00

  • PCV50 THE COST OF ATRIAL FIBRILLATION IN SWEDEN

    Nov 1, 2010, 00:00

  • PMS51 PATIENT PREFERENCES FOR SEVERE OSTHEOPOROSIS IN SPAIN- A DISCRETE CHOICE EXPERIMENT

    Nov 1, 2010, 00:00

  • PND5 BUDGET-IMPACT MODEL TO TEST EFFECTS OF CHANGING RUFINAMIDE TIER STATUS FROM A PAYER PERSPECTIVE

    Nov 1, 2010, 00:00

  • PCV99 COMPLIANCE AND PERSISTENCE WITH ANTIHYPERTENSIVES IN THE NETHERLANDS; A COMPARATIVE ANALYSIS WITH SPECIFIC FOCUS ON RAAS INTERVENING AGENTS

    Nov 1, 2010, 00:00

  • PHP33 CHINESE PAYERS VIEW OF PHARMACEUTICAL VALUE ATTRIBUTES- WHICH EVIDENCE DRIVES ACCESS?

    Nov 1, 2010, 00:00

  • PSS23 THE USE AND MISUSE OF ANTIBIOTICS FOR UPPER RESPIRATORY TRACT INFECTION

    Nov 1, 2010, 00:00

  • PRS5 BUDESONIDE/FORMOTEROL PLUS TIOTROPIUM (BUD/FORM TIO)- A SYSTEMATIC REVIEW AND ADJUSTED INDIRECT COMPARISON BETWEEN TWO ALTERNATIVE TRIPLE TREATMENTS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    Nov 1, 2010, 00:00

  • PRS1 RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS IN SPECIAL POPULATIONS

    Nov 1, 2010, 00:00

  • MA1 HOW TO HANDLE THE MAPPING PROBLEM IN COST-UTILITY ANALYSES?

    Nov 1, 2010, 00:00

  • PCV4 EFFECT OF PRETREATMENT WITH ANGIOTENSIN-CONVERTING ENZYME INHIBITORS ON IN-HOSPITAL MORTALITY AFTER ACUTE ISCHEMIC STROKE

    Nov 1, 2010, 00:00

  • PMC1 BEST PRACTICES IN REPORTING OF PROSPECTIVE OBSERVATIONAL STUDIES

    Nov 1, 2010, 00:00

  • PHP33 RATIONING IN PRACTICE- EQUITY IN WAITING TIMES FOR ELECTIVE SURGERY IN SWEDEN

    Nov 1, 2010, 00:00

  • PCN9 FIRST YEAR MEDICAL CARE COSTS ASSOCIATED WITH HEPATOCELLULAR CARCINOMA IN A MEDICAID POPULATION

    Nov 1, 2010, 00:00

  • PDB6 PERFORMANCES OF COMORBIDITY MEASURES IN HEALTH CARERELATED BEHAVIORS AND OUTCOMES IN TYPE 2 DIABETES

    Nov 1, 2010, 00:00

  • PHP127 ADOPTING A FINANCIAL RISK-SHARING SCHEME FOR NEW TECHNOLOGIES ADDED TO THE NATIONAL LIST OF HEALTH SERVICES IN ISRAEL- STAKEHOLDERS STATED INCENTIVES AND DISINCENTIVES

    Nov 1, 2010, 00:00

  • PMC58 SYSTEMATIC REVIEW OF STATISTICAL METHODS OF META-ANALYSIS AND INDIRECT COMPARISON POTENTIALLY AVAILABLE TO USE IN SYSTEMATIC REVIEWS-RESULTS FROM THE FIRST PART OF EBAYESMET PROJECT

    Nov 1, 2010, 00:00

  • PIH48 ANTIDEPRESSANT PRESCRIBING TO PATIENTS AGED 18 YEARS AND YOUNGER- A PHARMACOEPIDEMIOLOGICAL STUDY

    Nov 1, 2010, 00:00

  • PGI2 A SYSTEMATIC REVIEW AND META-ANALYSIS OF LITERATURE ASSESSING CLINICAL EFFICACY OF TREATMENTS FOR PATIENTS WITH HBEAG-POSITIVE CHRONIC HEPATITIS B

    Nov 1, 2010, 00:00

  • PSS29 INTERNATIONAL CO-VALIDATION OF A NEW INTERNATIONAL QUALITY OF LIFE INSTRUMENT SPECIFIC TO PHYSICAL APPEARANCE- BEAUTYQOL

    Nov 1, 2010, 00:00

  • PIN8 COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON (ALFA-2B) WITH RIBAVIRIN COMPARED WITH PEGINTERFERON (ALFA-2A) WITH RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C

    Nov 1, 2010, 00:00

  • PCN125 ECONOMIC AND PATIENT-REPORTED OUTCOMES OF OUTPATIENT HOME-BASED VERSUS INPATIENT HOSPITAL-BASED CHEMOTHERAPY FOR PATIENTS WITH COLORECTAL CANCER

    Nov 1, 2010, 00:00

  • PDB94 MARKOV AND MONTE-CARLO MODELS IN THE PROGRESSION OF DIABETES MELLITUS- A LITTERATURE REVIEW TO IDENTIIFY THE FACTORS INFLUENCING THE CHOICE OF THE TYPE OF MODEL

    Nov 1, 2010, 00:00

  • PDB27 INDIRECT COSTS OF ILLNESS FOR DIABETES IN PORTUGAL

    Nov 1, 2010, 00:00

  • PCV46 A SURVEY EXPLORING KNOWLEDGE AND PERCEPTIONS OF GENERAL PRACTITIONERS TOWARD THE USE OF GENERIC MEDICINES IN THE NORTHERN STATE OF MALAYSIA

    Nov 1, 2010, 00:00

  • PMH56 INNOVATIONS IN COMBINING PATIENT REPORTED OUTCOMES WITH COGNITIVE TESTING DATA TO STREAMLINE AND LEVERAGE REAL-TIME DATA COLLECTION

    Nov 1, 2010, 00:00

  • PHP107 ECONOMIC EVIDENCE REQUIREMENTS- COMPARISON BETWEEN HTA AGENCIES AND IMPLICATIONS FOR MANUFACTURERS

    Nov 1, 2010, 00:00

  • PCN55 COST OF TREATMENT OF BREAST CANCER IN RUSSIA

    Nov 1, 2010, 00:00

  • PND25 ECONOMIC EVALUATION OF NATALIZUMAB IN THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS IN 4 EUROPEAN COUNTRIES

    Nov 1, 2010, 00:00

  • PCN18 RETROSPECTIVE DATABASE ANALYSIS OF THE EFFECT OF ZOLEDRONIC ACID ON SKELETAL-RELATED EVENTS IN MEN WITH PROSTATE CANCER AND BONE METASTASES

    Nov 1, 2010, 00:00

  • PIN69 OUTPATIENT ANTIBIOTIC USE IN PRIMARY HEALTH CARE IN NIS REGION

    Nov 1, 2010, 00:00

  • PHP45 COSTS OF CARE UNDER A HEALTH CARE PLAN IN THE LAST 5 YEARS OF LIFE OF BENEFICIARIES-DATA FROM THE REAL WORLD

    Nov 1, 2010, 00:00

  • PSS3 EPIDEMIOLOGY, COSTS AND QUALITY OF LIFE IN PATIENT WITH SEVERE CHRONIC HAND ECZEMA

    Nov 1, 2010, 00:00

  • PCV49 ESTIMATING THE COST OF ATRIAL FIBRILLATION IN GREECE

    Nov 1, 2010, 00:00

  • PHP103 NICE GUIDANCE-AN ANALYSIS OF LEVELS OF RESTRICTION BY DISEASE AREA

    Nov 1, 2010, 00:00

  • PIN58 REPORT ON A PILOT STUDY OF THE SIMPILL REALTIME MEDICATION ADHERENCE SYSTEM IN TUBERCULOSIS PATIENTS IN CAPE TOWN, SOUTH AFRICA

    Nov 1, 2010, 00:00

  • PCN165 INFLATION ANALYSIS AS A TOOL TO ASSESS COST-EFFECTIVENESS OF CANCER TREATMENT

    Nov 1, 2010, 00:00

  • PDB5 IMPROVING PATIENT KNOWLEDGE AND CLINICAL OUTCOMES THROUGH A MEDICATION THERAPY MANAGEMENT (MTM) PROGRAM

    Nov 1, 2010, 00:00

  • PIN44 COST-EFFECTIVENESS ANALYSIS OF 1 YEAR PEGINTERFERON ALFA-2A VERSUS 4 YEARS ENTECAVIR FOR THE TREATMENT OF HBEAG-POSITIVE CHRONIC HEPATITIS B IN CHINA

    Nov 1, 2010, 00:00

  • PIH13 PATTERNS AND COSTS OF HOSPITALIZATIONS IN ELDERLY PATIENTS IN RIO DE JANEIRO, BRAZIL

    Nov 1, 2010, 00:00

  • PRS29 COST-EFFECTIVENESS OF SALMETEROL/FLUTICASONE PROPIONATE COMBINATION VERSUS LEUKOTRIENE MONTELUKAST FOR THE CONTROL OF PERSISTENT ASTHMA IN CHILDREN

    Nov 1, 2010, 00:00

  • PIH25 PERSPECTIVE OF THAI HEALTH-CARE PROFESSIONALS ON THAI HERBAL MEDICINE POLICY

    Nov 1, 2010, 00:00

  • PRS45 OPTIMIZATION OF GUIDELINES SUSTAINABILITY BY EVALUATING FACTORS PREDICTING TREATMENT RESPONSE IN PATIENTS WITH ALLERGIC RHINITIS

    Nov 1, 2010, 00:00

  • PDB79 DURATION OF FIRST INSULIN THERAPY IN PREVIOUSLY UNCONTROLLED TYPE 2 DIABETES- COMPARISON OF INSULINS GLARGINE, DETEMIR AND NPH AND ASSOCIATION WITH GLYCEMIC CONTROL

    Nov 1, 2010, 00:00

  • PND13 A PROSPECTIVE STUDY OF THE FINANCIAL COSTS OF MULTIPLE SCLEROSIS AT DIFFERENT STAGES OF THE ILLNESS IN IRAN

    Nov 1, 2010, 00:00

  • PND21 COST-EFFECTIVENESS OF TRANSDERMAL PATCH (ROTIGOTINE) IN PATIENTS WITH PARKINSON DISEASE IN MEXICO

    Nov 1, 2010, 00:00

  • PCV37 POTENTIAL FOR PATIENT CONFUSION FROM BRAND SUBSTITUTION OF STATINS IN AUSTRALIA

    Nov 1, 2010, 00:00

  • DS4 HERBAL PRODUCTS SAFETY- AN APPLICATION OF HEALTH PRODUCT VIGILANCE CENTER DATABASE

    Nov 1, 2010, 00:00

  • PSS13 COSTS AND EFFECTS OF FIXED COMBINATION THERAPIES IN OPEN ANGLE GLAUCOMA

    Nov 1, 2010, 00:00

  • PHP28 THE COLLECTION AND USE OF 'REAL WORLD' DATA- INDUSTRY VIEWS

    Nov 1, 2010, 00:00

  • PCN12 EFFICACY OF SECOND LINE TREATMENTS IN PATIENTS WITH METASTATIC HORMONE REFRACTORY PROSTATE CANCER (MHRPC) IS NOT DEMONSTRATED BY PUBLISHED EVIDENCE FROM NONRANDOMIZED TRIALS

    Nov 1, 2010, 00:00

  • PRS22 COST OF COPD IN POLAND

    Nov 1, 2010, 00:00

  • PSY21 THE IMPACT OF COMORBIDITY ON INFLAMMATORY BOWEL DISEASE HEALTH COSTS

    Nov 1, 2010, 00:00

  • PCN1 THE EVALUATION OF ADR ONLINE REPORTING OF RADIOPAQUE AGENTS IN A UNIVERSITY HOSPITAL IN TAIWAN

    Nov 1, 2010, 00:00

  • PIN13 BURDEN AND MEDICAL COSTS OF ANOGENITAL WARTS IN BANGKOK, THAILAND

    Nov 1, 2010, 00:00

  • PDB34 THE ECONOMIC VALUE OF THE EASYPOD ELECTRONIC AUTOINJECTOR IN IMPROVING THE RESPONSE TO GROWTH HORMONE (GH) IN CHILDREN WITH IDIOPATHIC GROWTH HORMONE DEFICIENCY (IGHD)- A COST-CONSEQUENCE ANALYSIS

    Nov 1, 2010, 00:00

  • PCN133 EPICLIN-LUNG STUDY- NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENT QUALITY OF LIFE AND HEALTH-STATE ASSESSMENT

    Nov 1, 2010, 00:00

  • PMC10 RELIABILITY OF MANUFACTURERS BUDGET IMPACT ESTIMATES IN POLAND

    Nov 1, 2010, 00:00

  • PCV124 IMPACT OF REGIONAL MEASURES IN THE SALES OF THE RENINANGIOTENSIN SYSTEM ANTAGONISTS IN SPAIN

    Nov 1, 2010, 00:00

  • PMS45 PRODUCTIVITY COSTS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN SOUTH KOREA

    Nov 1, 2010, 00:00

  • PHP44 APPLICATION OF PERATOS PRINCIPLE TO UNDERSTAND COST DRIVERS IN HEALTH CARE

    Nov 1, 2010, 00:00

  • PCN37 BI OF IRESSA IN NSCLC IN THE NETHERLANDS-A HOSPITAL PERSPECTIVE

    Nov 1, 2010, 00:00

  • PCN26 PHARMACOECONOMIC EVALUATION OF NILOTINIB IN TREATING TAIWAN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML)

    Nov 1, 2010, 00:00

  • HT1 EARLY ALERT SYSTEMS FOR NEW PHARMACEUTICALS-DO THEY HAVE AN IMPACT ON PHARMACEUTICAL REIMBURSEMENT DECISIONS?- A CROSS-NATIONAL COMPARISON

    Nov 1, 2010, 00:00

  • PSY60 RESULTS FROM A COMPREHENSIVE LITERATURE REVIEW OF HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS)- MORE RESEARCH IS NEEDED?

    Nov 1, 2010, 00:00

  • PMC44 EXPERTS JUDGEMENT ON PATIENT-CENTRED COORDINATED CARE

    Nov 1, 2010, 00:00

  • PSY52 DEVELOPMENT AND CONTENT VALIDATION OF A MULTICENTRIC CASTLEMANS DISEASE SYMPTOM SCALE

    Nov 1, 2010, 00:00

  • PIN2 ESTIMATED IMPACT OF SUSTAINED VIROLOGICAL RESPONSE (SVR) ON LIFE EXPECTANCY, QUALITY-ADJUSTED LIFE-YEARS (QALYS) AND LIFETIME COSTS IN CHRONIC HEPATITIS C (CHC) PATIENTS

    Nov 1, 2010, 00:00

  • PIH19 ETHNIC/RACIAL DIFFERENCE IN SELF-ASSESSMENT OF HEALTH STATUS IN THE GENERAL US POPULATION

    Nov 1, 2010, 00:00

  • PCV74 ONE-YEAR COST-EFFECTIVENESS OF CYTOCHROME P450 2C19 GENOTYPE-GUIDED ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROMES IN THE UNITED KINGDOM

    Nov 1, 2010, 00:00

  • PCN88 COST-EFFECTIVENESS ANALYSIS OF CANCER TREATMENTS IN SOUTH OF IRAN

    Nov 1, 2010, 00:00

  • PDB23 THE EFFECT OF METFORMIN BRAND SHIFT BY HOSPITAL ON DIABETIC TREATMENT OUTCOMES

    Nov 1, 2010, 00:00

  • PCN15 SYSTEMATIC REVIEW OF LAPATINIB PLUS LETROZOLE WITH OTHER FIRST LINE TREATMENTS FOR HORMONE POSITIVE (HR ADVANCED OR METASTATIC BREAST CANCER (MBC)

    Nov 1, 2010, 00:00

  • PIN59 DEVELOPMENT OF A SPECIFIC QUESTIONNAIRE TO ASSESS TREATMENT ADHERENCE OF PATIENTS WITH HCV INFECTION- ADHEPTA STUDY

    Nov 1, 2010, 00:00

  • PUK2 COMORBIDITY EFFECT ON HOSPITAL READMISSION RATES IN PATIENTS WITH RENAL FAILURE

    Nov 1, 2010, 00:00

  • PHP62 VALUE OF CONGRESS ABSTRACTS OF COST-EFFECTIVENESS STUDIES FOR DECISION MAKERS

    Nov 1, 2010, 00:00

  • PHP20 TRENDS IN DRUG EXPENDITURES IN SONGKHLA HOSPITAL

    Nov 1, 2010, 00:00

  • PSY3 HEALTH-CARE UTILIZATION AND COST IN PERSONS WITH FACTOR VIII DEFICIENCY- RESULTS OF THE HUGS VA STUDY

    Nov 1, 2010, 00:00

  • PIH61 CALIBRATION OF A DISCRETE EVENT SIMULATION MODEL OF NATURAL HISTORY OF HPV-RELATED DISEASES

    Nov 1, 2010, 00:00

  • PIN20 A MODELED ECONOMIC EVALUATION OF RALTEGRAVIR COMPARED TO STANDARD PRACTICE IN AUSTRALIA FOR TREATMENT NAVE PATIENTS WITH HIV

    Nov 1, 2010, 00:00

  • PCN47 CHANGE OF ANTIFUNGAL TREATMENT PATTERNS AND ASSOCIATED COSTS IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML) AFTER CHEMOTHERAPY IN A GERMAN HOSPITAL FROM 2004 TO 2006

    Nov 1, 2010, 00:00

  • PMH25 COMPARISON OF ESCITALOPRAM VS. CITALOPRAM AND VENLAFAXINE IN THE TREATMENT OF MAJOR DEPRESSION IN SPAIN- CLINICAL AND ECONOMIC CONSEQUENCES

    Nov 1, 2010, 00:00

  • PRS43 COMPLIANCE TO GOLD GUIDELINES IN THE TREATMENT OF COPD- APPROPRIATENESS AND POTENTIAL COST SAVING IN ITALY

    Nov 1, 2010, 00:00

  • PMS74 CLAIMS-BASED SEVERITY INDEX FOR RHEUMATOID ARTHRITIS FROM HEALTH CARE CLAIMS DATA

    Nov 1, 2010, 00:00

  • PIN73 FACTORS AFFECTING THE DECISION TO RECEIVE VACCINATION FOR INFLUENZA VIRUS H1N1

    Nov 1, 2010, 00:00

  • PGI7 ECONOMIC BURDEN OF OPIOID INDUCED CONSTIPATION IN SPAIN

    Nov 1, 2010, 00:00

  • PCV11 PLATELET FUNCTION TESTS ARE HIGHLY VARIABLE WHEN USED TO IDENTIFY PATIENTS RESISTANT TO CLOPIDOGREL

    Nov 1, 2010, 00:00

  • PMH28 EFFECT OF PREGABALIN ON COSTS AND CONSEQUENCES IN PATIENTS WITH REFRACTORY SEVERE GENERALIZED ANXIETY DISORDER AND CONCOMITANT SEVERE SYMPTOMS OF DEPRESSION IN DAILY MEDICAL PRACTICE

    Nov 1, 2010, 00:00

  • PDB46 COST-EFFECTIVENESS OF NEW ANTIDIABETICS IN TYPE 2 DIABETES- A REVIEW

    Nov 1, 2010, 00:00

  • PMC19 THE THRESHOLD PRICING MODEL- NOT JUST ANOTHER COSTEFFECTIVENESS MODEL

    Nov 1, 2010, 00:00

  • PMH16 THE ECONOMIC AND HUMANISTIC BURDEN OF ILLNESS IN GENERALISED ANXIETY DISORDER (GAD)- A RETROSPECTIVE DATABASE ANALYSIS IN EUROPE

    Nov 1, 2010, 00:00

  • PSY28 COST OF INHIBITOR DEVELOPMENT IN PATIENTS WITH SEVERE HEMOPHILIA A IN SPAIN

    Nov 1, 2010, 00:00

  • PRS32 REGIONAL DIFFERENCES AS A BASIS FOR SENSITIVITY ANALYSIS OF COST-EFFECTIVENESS OF SALMETEROL FLUTICASONE PROPIONATE (SAL/FP) VS. INHALED CORTICOSTEROIDS (MONO-ICS)

    Nov 1, 2010, 00:00

  • AD2 THE SOCIETAL BURDEN OF POOR PERSISTENCE TO TREATMENT OF OSTEOPOROSIS IN SWEDEN

    Nov 1, 2010, 00:00

  • PIH7 ECONOMIC EVALUATION OF HUMAN PAPILLOMAVIRUS (HPV) VACCINATIONS IN THE PREVENTION OF CERVICAL CANCER

    Nov 1, 2010, 00:00

  • PRS1 RISK OF SERIOUS ASTHMA EXACERBATIONS ASSOCIATED WITH LONG-ACTING-BETA-AGONISTS AMONG MEDICAID PATIENTS WITH ASTHMA-A RETROSPECTIVE COHORT STUDY

    Nov 1, 2010, 00:00

  • PIH65 USING A GENERALIZED ADDITIVE MODEL TO EXAMINE THE RELATIONSHIP BETWEEN BODY MASS INDEX AND HEALTH-RELATED QUALITY OF LIFE IN THE ELDERLY POPULATION-RESULTS FROM THE POPULATION-BASED GERMAN KORA-AGE STUDY

    Nov 1, 2010, 00:00

  • PDB82 PRESCRIBED DAILY DOSES OF ONCE-DAILY LIRAGLUTIDE IN THE GERMAN STATUTORY HEALTH INSURANCE (SHI)

    Nov 1, 2010, 00:00

  • PSS7 THE ECONOMIC COST OF TREATING PATIENTS WITH AGE-RELATED MACULAR DEGENERATION IN SPAIN

    Nov 1, 2010, 00:00

  • PIH3 A COSTING STUDY COMPARING MIDWIFERY GROUP PRACTICE WITH USUAL CARE IN AN AUSTRALIAN METROPOLITAN HOSPITAL

    Nov 1, 2010, 00:00

  • PMS3 THE RISK OF REFRACTURE ASSOCIATED WITH THE COMPLIANCE AND THE PERSISTENCE WITH BISPHOSPHONATE THERAPY IN TAIWAN

    Nov 1, 2010, 00:00

  • PCN153 HOW DO HTA AGENCIES RECOGNIZE AND REWARD INNOVATION? CASE STUDIES IN BREAST CANCER AND COLORECTAL CANCER

    Nov 1, 2010, 00:00

  • PCV90 THE COST-EFFECTIVENESS OF ROSUVASTATIN VERSUS SIMVASTATIN FOR THE PREVENTION OF CARDIOVASCULAR MORBIDITY AND MORTALITY IN PATIENTS WITH HIGH BASELINE RISK-A SWEDISH ECONOMIC EVALUATION BASED UPON THE JUPITER TRIAL

    Nov 1, 2010, 00:00

  • PDB66 THE 8-ITEM MORISKY MEDICATION ADHERENCE SCALE MMAS- TRANSLATION AND VALIDATION STUDY OF THE MALAYSIAN VERSION

    Nov 1, 2010, 00:00

  • PDB70 MEASUREMENT OF HRQOL USING EQ-5D IN TYPE 2 DIABETES MELLITUS PATIENTS TREATED WITH ORAL ANTI-DIABETIC DRUGS IN CHINA

    Nov 1, 2010, 00:00

  • PSS5 COST OF GLAUCOMA IN THE UNITED KINGDOM ACCORDING TO THE UK GPRD

    Nov 1, 2010, 00:00

  • PCV63 COST OF ABLATION PROCEDURES FOR ATRIAL FIBRILLATION- RESULTS FROM THE AIAC SURVEY

    Nov 1, 2010, 00:00

  • PCN135 IMPROVEMENT IN QUALITY OF LIFE OUTCOMES IN INTERFERONALPHA TREATED PATIENTS COMPARED TO SUNITINIB IN ADVANCE OR METASTATIC RENAL CELL CARCINOMA

    Nov 1, 2010, 00:00

  • PCV29 PREVALENCE, CHARACTERISTICS, AND IN-HOSPITAL OUTCOMES OF METABOLIC SYNDROME IN ACUTE CORONARY DISEASE PATIENTS IN OMAN

    Nov 1, 2010, 00:00

  • CN4 CAN WE CORRECTLY TARGET HIGH-COST THERAPIES? THE DIAGNOSTIC ACCURACY OF HISTOLOGY IN DIFFERENTIATING BETWEEN SQUAMOUS AND NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

    Nov 1, 2010, 00:00

  • PCN106 INDIRECT COST IN NON-SMALL CELL LUNG CANCER (NSCLC)- A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2010, 00:00

  • PCN157 REASONS FOR DISCONTINUATION OF HORMONAL THERAPY IN BREAST CANCER PATIENTS ACROSS FIVE EUROPEAN COUNTRIES

    Nov 1, 2010, 00:00

  • PCN147 MEDICAL RESOURCES UTILIZATION OF FIVE MOST PREVALENT CANCERS IN TAIWAN (LUNG CANCER, LIVER CANCER, COLORECTAL CANCER, GASTRIC CANCER, AND BREST CANCER)- 2001~2007

    Nov 1, 2010, 00:00

  • PDB4 A CROSS-SECTIONAL STUDY ON GLYCEMIC CONTROL AND ADVERSE EVENTS IN TYPE 2 DIABETES MELLITUS PATIENTS TREATED WITH ORAL ANTIDIABETIC DRUGS IN CHINA

    Nov 1, 2010, 00:00

  • PCN50 BURDEN OF HOSPITALIZATIONS FOR HEPATOCELLULAR CARCINOMA PATIENTS IN A US POPULATION

    Nov 1, 2010, 00:00

  • PMS24 OSTEOPOROSIS COSTS IN ITALY. INTERIM RESULTS OF THE BLOCK STUDY

    Nov 1, 2010, 00:00

  • PHP4 POST HEALTH CARE REFORM PERCEPTIONS IN THE US- CONSUMER PULSE SURVEY

    Nov 1, 2010, 00:00

  • PMC39 EXAMINING ITEM RESPONSE PATTERNS OVER TIME IN A HEALTH PROFILE MEASURE USING US NATIONAL REPRESENTATIVE SAMPLES- A MULTI-FACET MODEL APPROACH

    Nov 1, 2010, 00:00

  • PCN48 COST-EFFECTIVENESS COMPARISON OF APPROACHES FOR LOW-RISK PROSTATE CANCER CARE-THE NEED TO BALANCE COST AND UTILITY

    Nov 1, 2010, 00:00

  • PDB73 THE PANORAMA PAN-EUROPEAN SURVEY- HYPOGLYCAEMIA ASSOCIATED WITH DIFFERENT PHARMACOLOGICAL TREATMENTS FOR TYPE 2 DIABETES

    Nov 1, 2010, 00:00

  • PCV61 ECONOMICS ESTIMATION OF SIDE EFFECTS CORRECTION ANTIHYPERTENSIVE MEDICAL PRODUCTS OF INHIBITORS-ACE IN RUSSIAN HEALTH

    Nov 1, 2010, 00:00

  • PSY23 COST OF POMPE DISEASE IN POLAND IN 2008 AND 2009

    Nov 1, 2010, 00:00

  • PCN151 TARGETED CANCER THERAPIES- PRICING, ACCESS, AND UPTAKE

    Nov 1, 2010, 00:00

  • PUK24 A COST-UTILITY ANALYSIS OF CINACALCET IN SECONDARY HYPERPARATHYROIDISM (SHPT) IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2010, 00:00

  • PIH8 ESTIMATED HEALTH AND ECONOMIC IMPACT OF QUADRIVALENT HPV TYPES 6, 11, 16, 18 VACCINE IN THAILAND USING A TRANSMISSION DYNAMIC MODEL

    Nov 1, 2010, 00:00

  • PSS9 SUMMARIZING UTILITY VALUES OF PATIENTS WITH AGE-RELATED MACULAR DEGENERATION-A SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2010, 00:00

  • PSY4 BIOLOGICAL AGENTS FOR THE TREATMENT OF NAIL PSORIASIS- A SYSTEMATIC REVIEW OF THE LITERATURE

    Nov 1, 2010, 00:00

  • PCV112 QUALITY OF LIFE AND DEPRESSION AMONG ADULTS WITH TYPE 2 DIABETES MELLITUS, HYPERTENSION, AND OBESITY

    Nov 1, 2010, 00:00

  • PDB81 TIME TO ADD-ON MEDICATION USE FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) WHO FAILED METFORMIN MONOTHERAPY

    Nov 1, 2010, 00:00

  • PCN43 COST COMPARISON OF ERLOTINIB VERSUS PEMETREXED FOR THE FIRST-LINE MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN ITALY

    Nov 1, 2010, 00:00

  • PHP94 IS IT COST-EFFECTIVE TO CHANGE THE BEHAVIOR OF HEALTH CARE PROFESSIONALS?

    Nov 1, 2010, 00:00

  • PMH59 EVALUATION OF THE EFFECT OF ARIPIPRAZOLE ON QUALITY OF LIFE IN PATIENTS WITH SCHIZOPHRENIA IN A PROSPECTIVE, MULTICENTRE, OPEN-LABEL STUDY

    Nov 1, 2010, 00:00

  • PCN84 COST-EFFECTIVENESS OF ERLOTINIB IN FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FIT ELDERLY PATIENTS- AN ECONOMICAL ANALYSIS OF A PROSPECTIVE PHASE 2 STUDY (GFPC 0504)

    Nov 1, 2010, 00:00

  • CN3 QUALITY OF LIFE IN ADVANCED CANCER PATIENT-COMPARISON OF PATIENT-REPORTED OUTCOME (PRO) AND PROXIES ASSESSMENT

    Nov 1, 2010, 00:00

  • PIH35 DEMONSTRATING CONCEPTUAL EQUIVALENCE ACROSS MULTIPLE CULTURES- TRANSLATION AND LINGUISTIC VALIDATION OF THE IPAQ

    Nov 1, 2010, 00:00

  • PHP46 COSTS OF TREATING TERMINAL PATIENTS IN DIFFERENT BELGIAN HEALTH CARE SETTINGS

    Nov 1, 2010, 00:00

  • PRS10 TRENDS IN ANTI-ASTHMA MEDICATION USE IN DUTCH CHILDREN FROM 1998 UNTIL 2007

    Nov 1, 2010, 00:00

  • PMH73 IMPACT OF PLACEBO RUN-IN PERIOD ON RELATIVE TREATMENT EFFECT IN GENERALIZED ANXIETY DISORDER (GAD)

    Nov 1, 2010, 00:00

  • PCV22 THE INFLUENCE OF METEOROLOGICAL FACTORS ON CEREBRAL INFARCTION, INTRACEREBRAL HEMORRHAGE, SUBARACHNOID HEMORRHAGE AND TRANSIENT ISCHEMIC ATTACK

    Nov 1, 2010, 00:00

  • PGI16 COST-EFFECTIVENESS OF ON-TREATMENT MONITORING OF HBSAG LEVELS TO PREDICT RESPONSE TO PEGINTERFERON-ALPHA-2A FOR HEPATITIS B TREATMENT UNDER THE PUBLIC PAYER PERSPECTIVE IN BRAZIL

    Nov 1, 2010, 00:00

  • PHP112 ANALYSIS OF PHARMACISTS INTERVENTIONS OF ELECTRONIC PRESCRIPTIONS AT SULTAN QABOOS UNIVERSITY HOSPITAL IN OMAN

    Nov 1, 2010, 00:00

  • PDB12 COST-EFFECTIVENESS ANALYSIS OF GLIMEPIRIDE OR PIOGLITAZONE IN COMBINATION WITH METFORMIN IN TYPE-II DIABETIC PATIENTS IN KOREA

    Nov 1, 2010, 00:00

  • PUK27 TIME SAVINGS WITH Q4W (ONCE-MONTHLY) C.E.R.A.- A TIME AND MOTION STUDY CONDUCTED IN HEMODIALYSIS CENTRES IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2010, 00:00

  • PDB38 ADDITION OF INCRETIN-THERAPY TO METFORMIN IN TYPE-2DIABETES MELLITUS (T2DM)- COST-EFFECTIVENESS OF LIRAGLUTIDE VERSUS SITAGLIPTIN FROM THE PERSPECTIVE OF THE GERMAN STATUTORY HEALTH INSURANCE (SHI)

    Nov 1, 2010, 00:00

  • PHP121 INSPECTION OF THE PHARMACEUTICAL COMPANIES IN IRAN BY INSPECTION SOFTWARE

    Nov 1, 2010, 00:00

  • PMH18 THE COSTS OF DEPRESSION IN SWITZERLAND

    Nov 1, 2010, 00:00

  • PDB44 THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS SULFONYLUREA (SU) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN GERMANY

    Nov 1, 2010, 00:00

  • PCV18 COMPARISON OF MIXED DYSLIPIDEMIAS AMONG HIGH CARDIOVASCULAR RISK PRIMARY CARE PATIENTS- RESULTS OF A POOLED ANALYSIS OF PRIMULA DATA FROM CANADA, SPAIN, SWEDEN, AND THE UNITED KINGDOM

    Nov 1, 2010, 00:00

  • PHP13 FACTORS ASSOCIATED WITH THE PROVISION OF LAPAROSCOPIC SURGERY IN THAILAND- RESULTS FROM THE NATIONWIDE INPATIENT DATABASE

    Nov 1, 2010, 00:00

  • PCV67 COST-EFFECTIVENESS OF FONDAPARINUX VS. ENOXAPARIN IN NON-ST-ELEVATION ACUTE CORONARY SYNDROMES IN RUSSIA

    Nov 1, 2010, 00:00

  • PMH14 ADHERENCE AND PERSISTENCE WITH DULOXETINE VERSUS ESCITALOPRAM AMONG HIGH HEALTH-CARE RESOURCES UTILIZERS WITH MAJOR DEPRESSIVE DISORDER

    Nov 1, 2010, 00:00

  • PMS56 DETERMINING THE OPTIMAL TIMING FOR TOTAL KNEE REPLACEMENT

    Nov 1, 2010, 00:00

  • PCV23 EVALUATING THE BENEFITS WITH TELECARE AMONG RESIDENTS IN NURSING HOMES IN TAIWAN

    Nov 1, 2010, 00:00

  • PCV110 HOW PATIENTS EXPERIENCE COULD INFLUENCE THEIR PREFERENCES TOWARD TREATMENT FOR ABDOMINAL AORTIC ANEURYSM- RESULTS FROM THE PREFER STUDY

    Nov 1, 2010, 00:00

  • PCN53 ANALYSIS OF SOCIOECONOMIC BUREDN OF HEPATOCELLULAR CARCINOMA IN RUSSIA

    Nov 1, 2010, 00:00

  • PCV28 HEALTH-RELATED QUALITY OF LIFE AFTER PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROMES

    Nov 1, 2010, 00:00

  • PCN16 COST-EFFECTIVENESS ANALYSIS OF K-RAS TESTING AND CETUXIMAB FOR METASTATIC COLORECTAL CANCER IN JAPAN

    Nov 1, 2010, 00:00

  • PIH18 COST-EFFECTIVENESS OF COMBINATION THERAPY WITH DUTASTERIDE AND TAMSULOSIN FOR THE TREATMENT OF MODERATE TO SEVERE BENIGN PROSTATIC HYPERPLASIA IN SPAIN

    Nov 1, 2010, 00:00

  • PSS30 DISCREPANCY IN PATIENT AND PHYSICIAN GLOBAL ASSESSMENTS OF DERMATOLOGIC DISEASES

    Nov 1, 2010, 00:00

  • PSS10 CLINICAL AND COST-EFFECTIVENESS EVALUATION OF A LOW FRICTION AND SHEAR PRODUCT IN THE MANAGEMENT OF PATIENTS AT RISK OF SKIN BREAKDOWN WITHIN A HOSPITAL SETTING

    Nov 1, 2010, 00:00

  • PHP129 ATTITUDES OF HUNGARIAN POPULATION TOWARD CO-PAYMENTS

    Nov 1, 2010, 00:00

  • PSY11 COSTS OF SUPPORTIVE CARE (SC) FOR THE TREATMENT OF MYELODISPLASTIC SYNDROME (MDS) IN BRAZIL- AN ANALYSIS FROM THE PRIVATE PAYERS PERSPECTIVE

    Nov 1, 2010, 00:00

  • PRS37 ASSOCIATION OF PATIENT-REPORTED INHALER SATISFACTION WITH PHYSICIAN-PERCEIVED COMPLIANCE WITH ASTHMA TREATMENT-RESULTS OF A CROSS-SECTIONAL STUDY IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2010, 00:00

  • PSY34 COST-EFFECTIVENESS OF TAPENTADOL PROLONGED-RELEASE (PR) COMPARED TO OXYCODONE AND MORPHINE IN PATIENTS WITH CHRONIC MODERATE TO SEVERE NON-CANCER PAIN IN SWEDEN

    Nov 1, 2010, 00:00

  • PMC32 MINIMALLY IMPORTANT DIFFERENCE OF THE TREATMENT SATISFACTION WITH MEDICINES QUESTIONNAIRE (SATMED-Q)

    Nov 1, 2010, 00:00

  • PIH17 COST-EFFECTIVENESS OF SEASONAL INFLUENZA VACCINATION IN PREGNANCY IS DEPENDENT ON VACCINATION EARLY IN FLU SEASON

    Nov 1, 2010, 00:00

  • PMH13 COSTS ASSOCIATED WITH ANTIPSYCHOTIC MEDICATIONS FOR PATIENTS WITH A BIPOLAR DIAGNOSIS AT CLINICALLY RECOMMENDED DOSES

    Nov 1, 2010, 00:00

  • PMS18 A BUDGET IMPACT MODEL FOR THE ECONOMIC ASSESSMENT OF TOCILIZUMAB IN THE TREATMENT OF RHEUMATOID ARTHRITIS PATIENTS IN ITALY

    Nov 1, 2010, 00:00

  • PHP12 PHYSICIANS VIEWS ON BIOMEDICAL TECHNOLOGY IN GREECE

    Nov 1, 2010, 00:00

  • PCV30 PERCEPTION OF PATIENTS ON WARFARIN THERAPY TOWARD PHARMACIST-MANAGED ANTICOAGULATION SERVICE IN AMBULATORY CARE SETTINGS IN SINGAPORE

    Nov 1, 2010, 00:00

  • PIN66 EVALUATION OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS RECEIVING ANTIRETROVIRAL THERAPY IN MAITAMA DISTRICT HOSPITAL, ABUJA NIGERIA

    Nov 1, 2010, 00:00

  • PMC46 TRANSLATION AND LINGUISTIC VALIDATION OF PRO MEASURES- RESPONSE OPTION ISSUES

    Nov 1, 2010, 00:00

  • PIN26 EARLY VS. LATE DETECTION OF HIV IN UK- COST CONSEQUENCE STUDY

    Nov 1, 2010, 00:00

  • PCN67 MANAGEMENT OF MALIGNANT ASCITES IN GERMANY-TREATMENT PATTERNS, RESOURCE CONSUMPTION, AND COSTS

    Nov 1, 2010, 00:00

  • PIN11 COST ANALYSIS OF ADVERSE DRUG EVENTS GROM GPO-VIRS AND GPO-VIRZ IN PEOPLE LIVING WITH HIV/AIDS IN THAILAND

    Nov 1, 2010, 00:00

  • PHP75 EVALUATION OF THE IMPACT OF INPATIENT CLINICAL PHARMACY SERVICES ON THE QUALITY AND COST OF PHARMACOTHERAPY IN INTERNAL MEDICINE WARDS

    Nov 1, 2010, 00:00

  • PIN6 A MULTIVARIATE MODEL- PREDICTORS OF DISEASE PROGRESSION IN HIV/AIDS PATIENTS IN WESTERN NEW YORK

    Nov 1, 2010, 00:00

  • PMS33 COST-EFFECTIVENESS OF TOCILIZUMAB FOR THE MANAGEMENT OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE PREVIOUS DMARD THERAPY IN MEXICO

    Nov 1, 2010, 00:00

  • PCN2 ASSESSMENT ON THE DECREASING USE OF NARCOTIC ANALGESICS BY USING CANCER PAIN ADJUVANTS

    Nov 1, 2010, 00:00

  • PSS32 THE EXPERIENCE OF EXTERNAL GENITAL WARTS AND GENITAL HERPES ON QUALITY OF LIFE

    Nov 1, 2010, 00:00

  • PND44 HEALTH RELATED QUALITY OF LIFE DEFICITS IN MULTIPLE SCLEROSIS-A POPULATION CONTROL ANALYSIS

    Nov 1, 2010, 00:00

  • PMS43 COST-UTILITY AND MULTINOMIAL EXPECTED VALUE OF PERFECT INFORMATION OF SEQUENCED TREATMENT WITH BIOLOGICS IN MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS- ANALYSIS BASED ON CLINICALLY MEANINGFUL RESPONSES

    Nov 1, 2010, 00:00

  • PCN123 DEVELOPMENT OF A COMPUTER-ADAPTIVE PATIENT REPORTED OUTCOME TOOL FOR THE SCREENING FOR PSYCHO-ONCOLOGICAL TREATMENT NEEDS

    Nov 1, 2010, 00:00

  • PCV92 THE HEALTH AND ECONOMIC IMPACT OF SWITCHING FROM ATORVASTATIN TO GENERIC SIMVASTATIN IN BELGIUM

    Nov 1, 2010, 00:00

  • BI2 MULTIPLE COHORT MODELING OF LONG-DURATION INTERVENTIONS- QUESTIONING TIME HORIZONS AND AGGREGATION ACROSS COHORTS

    Nov 1, 2010, 00:00

  • PGI14 COST-EFFECTIVENESS ANALYSIS ON THE USE OF TEGASEROD COMPARED TO STANDARD THERAPY IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITHIN AN INSTITUTIONAL SETTING IN MEXICO

    Nov 1, 2010, 00:00

  • HE2 NEW DRUGS AND THE GROWTH OF HEALTH EXPENDITURE- EVIDENCE FROM DIABETIC PATIENTS IN TAIWAN

    Nov 1, 2010, 00:00

  • PCN93 COST-MINIMIZATION ANALYSIS OF XELOX (CAPECITABINE OXALIPLATIN) AS ADJUVANT TREATMENT IN STAGE III COLON CANCER UNDER THE BRAZILIAN PRIVATE PAYER PERSPECTIVE

    Nov 1, 2010, 00:00

  • PIN39 COST-EFFECTIVENESS OF NUCLEIC ACID TEST SCREENING IN BLOOD DONATION FOR HIV IN BRAZIL

    Nov 1, 2010, 00:00

  • PHP7 AN EXPLORATORY STUDY EVALUATING THE PREPAREDNESS OF PRACTICING COMMUNITY PHARMACISTS IN MALAYSIA FOR MANAGEMENT ROLES

    Nov 1, 2010, 00:00

  • PDB86 HEALTH TECHNOLOGY ASSESSMENT OF DIABETES COMPOUNDS- THE POLISH PERSPECTIVE

    Nov 1, 2010, 00:00

  • PSS33 REAL-LIFE DOSING OF BIOLOGICS IN PLAQUE PSORIASIS-A GERMAN SURVEY

    Nov 1, 2010, 00:00

  • NI4 DO PATIENT ACCESS SCHEMES RESULT IN AN ACCEPTABLE ADMINISTRATIVE BURDEN?

    Nov 1, 2010, 00:00

  • PMS21 THE ACUTE CARE COSTS OF OSTEOPOROSIS-RELATED FRACTURES IN CANADA

    Nov 1, 2010, 00:00

  • PCN116 ANALYSIS OF THE EQ-5D QUESTIONNAIRE FOR PATIENTS WITH ADVANCED HER2-POSITIVE GASTRIC CANCER (HER2 AGC) BASED ON THE TRASTUZUMAB FOR GASTRIC CANCER (TOGA) STUDY

    Nov 1, 2010, 00:00

  • PCN27 THE COST OF CHEMOTHERAPY SIDE EFFECTS

    Nov 1, 2010, 00:00

  • PRS13 ECONOMIC IMPACT OF NON-ADHERENCE TO GOLD GUIDELINES IN COPD PATIENTS IN PRIMARY CARE IN SPAIN

    Nov 1, 2010, 00:00

  • PMS38 COST-EFFECTIVENESS OF RITUXIMAB VERSUS ALTERNATIVE ANTI-TUMOR NECROSIS FACTOR (TNF) THERAPY AFTER PREVIOUS FAILURE OF ONE ANTI-TNF AGENT FOR TREATMENT OF RHEUMATOID ARTHRITIS IN MEXICO

    Nov 1, 2010, 00:00

  • PND2 WARFARIN-ASSOCIATED INTRACRANIAL HEMORRHAGE

    Nov 1, 2010, 00:00

  • PHP59 EVOLUTION OF PUBLIC EXPENDITURE WITH PHARMACEUTICAL CARE IN BRAZIL DURING THE PERIOD 2005-2008

    Nov 1, 2010, 00:00

  • PGI11 RISK FACTORS AND COSTS ASSOCIATED TO NSAIDS THERAPIES IN ITALY- AN ADMINISTRATIVE DATABASE ANALYSIS

    Nov 1, 2010, 00:00

  • PMS4 NUMBER NEEDED TO TREAT FOR PATIENTS TO REPORT BROAD RELIEF FROM THE BURDEN OF RHEUMATOID ARTHRITIS WHEN TREATED WITH CERTOLIZUMAB PEGOL PLUS METHOTREXATE

    Nov 1, 2010, 00:00

  • PIN37 HEALTH ECONOMIC EVALUATION OF CONJUGATE PNEUMOCOCCAL VACCINES IN LATIN AMERICAN COUNTRIES

    Nov 1, 2010, 00:00

  • PDB92 CLINICAL AND ECONOMIC CONSEQUENCES OF THE PHARMACOLOGICAL HYPOGLYCEMIC TREATMENT OF TYPE 2 DIABETES IN CROATIA

    Nov 1, 2010, 00:00

  • PDB51 COST-EFFECTIVENESS OF EXENATIDE VERSUS INSULIN GLARGINE AND VERSUS BIPHASIC INSULIN ASPART FOR THE TREATMENT OF TYPE 2 DIABETES IN PORTUGAL- A LONG-TERM HEALTH ECONOMIC ANALYSIS

    Nov 1, 2010, 00:00

  • PIN27 COST-EFFECTIVENESS ANALYSIS OF HPV VACCINATION AGAINST CERVICAL CANCER IN YOUNG ADULT WOMEN IN ITALY

    Nov 1, 2010, 00:00

  • PIH7 BODY COMPOSITION CHANGES IN THE PREOPERATIVE PERIOD AND AFTER SURGERY

    Nov 1, 2010, 00:00

  • PIN18 A PILOT COST-OF-ILLNESS STUDY ON LONG TERM COMPLICATIONS/ SEQUELAE FOLLOWING ACUTE OTITIS MEDIA (AOM) IN BELGIUM

    Nov 1, 2010, 00:00

  • PIN50 COST-EFFECTIVENESS OF PEGINTERFERON ALPHA-2A VERSUS PEGINTERFERON ALPHA-2B FOR TREATMENT OF CHRONIC HEPATTIS C INFECTION IN MEXICO

    Nov 1, 2010, 00:00

  • PND35 COMPARISON OF ANALYIC HIERARCHY PROCESS AND CONJOINT ANALYSIS METHODS IN ASSESSING TREATMENT ALTERNATIVES IN STROKE REHABILITATION

    Nov 1, 2010, 00:00

  • PCV12 COMPARATIVE EFFICACY OF EZETIMIBE-STATIN COMBINATION THERAPY AND STATIN MONOTHERAPY IN PATIENTS WITH HYPERCHOLESTEROLEMIA- SYSTEMATIC REVIEW AND METAANALYSIS OF RANDOMISED CONTROLLED TRIALS

    Nov 1, 2010, 00:00

  • PMC9 A NEO-RICARDIAN APPROACH TOWARD DISCOUNTING

    Nov 1, 2010, 00:00

  • PSY2 THE USE OF ETANERCEPT FOR TREATMENT OF PSORIASIS IN REAL CLINICAL PRACTICE-NON-INTERVENTION OBSERVATIONAL STUDY

    Nov 1, 2010, 00:00

  • ME3 COST METHOD- A SIMPLE FRAMEWORK AND WORKING TOOL FOR BUDGET IMPACT ANALYSIS

    Nov 1, 2010, 00:00

  • PUK31 PSYCHOMETRIC VALIDATION OF THE SPANISH VERSION OF THE OVERACTIVE BLADDER QUESTIONNAIRE SHORT-FORM (OABQ-SF) TO ASSESS SEVERITY OF SYMPTOMS AND PATIENT HEALTH RELATED QUALITY OF LIFE IN SUBJECTS WITH OVERACTIVE BLADDER

    Nov 1, 2010, 00:00

  • PIN15 THE ECONOMIC BURDEN OF SURGICAL SITE INFECTION USING THERAPEUTIC ANTIBIOTIC UTILIZATION MEASURE-COMPARISON OF TWO TIME PERIODS

    Nov 1, 2010, 00:00

  • PMH9 CHARACTERISTICS OF OUTPATIENTS INITIATED ON OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA IN JAPAN

    Nov 1, 2010, 00:00

  • PDB59 HEALTH ECONOMIC EVALUATIONS COMPARING THE BASAL INSULIN ANALOGUE GLARGINE (GLA) WITH NEUTRAL PROTAMINE HAGEDORN (NPH) INSULIN IN INTENSIFIED INSULIN THERAPY (ICT) IN PATIENTS WITH TYPE 1 DIABETES-A SYSTEMATIC REVIEW

    Nov 1, 2010, 00:00

  • PCN22 ECONOMIC ANALYSIS OF CAPECITABINE PLUS OXALIPLATIN (XELOX) VERSUS FLUOROURACIL/LEUCOVORIN PLUS OXALIPLATIN (FOLFOX) IN THE TREATMENT OF ADVANCED GASTRIC CANCER IN CHINA

    Nov 1, 2010, 00:00

  • PCN142 WHAT IS THE CURRENT RD LANDSCAPE FOR METASTATIC BREAST CANCER? AN INVESTIGATION INTO RECENT CLINICAL TRIAL ACTIVITY

    Nov 1, 2010, 00:00
  • «
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130 (current)
  • »